Abdominal radiotherapy: a major determinant of metabolic syndrome in nephroblastoma and neuroblastoma survivors.

<h4>Background</h4>Reports on metabolic syndrome in nephroblastoma and neuroblastoma survivors are scarce. Aim was to evaluate the occurrence of and the contribution of treatment regimens to the metabolic syndrome.<h4>Patients and methods</h4>In this prospective study 164 sub...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Marjolein van Waas, Sebastian J C M M Neggers, Hein Raat, Caroline M van Rij, Rob Pieters, Marry M van den Heuvel-Eibrink
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2012
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/8ffadfb96ee947ea9b104ad69a00df51
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:8ffadfb96ee947ea9b104ad69a00df51
record_format	dspace
spelling	oai:doaj.org-article:8ffadfb96ee947ea9b104ad69a00df512021-11-18T08:05:00ZAbdominal radiotherapy: a major determinant of metabolic syndrome in nephroblastoma and neuroblastoma survivors.1932-620310.1371/journal.pone.0052237https://doaj.org/article/8ffadfb96ee947ea9b104ad69a00df512012-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23251703/pdf/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Background</h4>Reports on metabolic syndrome in nephroblastoma and neuroblastoma survivors are scarce. Aim was to evaluate the occurrence of and the contribution of treatment regimens to the metabolic syndrome.<h4>Patients and methods</h4>In this prospective study 164 subjects participated (67 adult long-term nephroblastoma survivors (28 females), 36 adult long-term neuroblastoma survivors (21 females) and 61 control subjects (28 females)). Controls were recruited cross-sectionally. Waist and hip circumference as well as blood pressure were measured. Body composition and abdominal fat were assessed by dual energy X-ray absorptiometry (DXA-scan). Laboratory measurements included fasting triglyceride, high density lipoprotein-cholesterol (HDL-C), glucose, insulin, low-density lipoprotein-cholesterol (LDL-C) and free fatty acids (FFA) levels.<h4>Results</h4>Median age at follow-up was 30 (range 19-51) years in survivors and 32 (range 18-62) years in controls. Median follow-up time in survivors was 26 (6-49) years. Nephroblastoma (OR = 5.2, P<0.0001) and neuroblastoma (OR 6.5, P<0.001) survivors had more components of the metabolic syndrome than controls. Survivors treated with abdominal irradiation had higher blood pressure, triglycerides, LDL-C, FFA and lower waist circumference. The latter can not be regarded as a reliable factor in these survivors as radiation affects the waist circumference. When total fat percentage was used as a surrogate marker of adiposity the metabolic syndrome was three times more frequent in abdominally irradiated survivors (27.5%) than in non-irradiated survivors (9.1%, P = 0.018).<h4>Conclusions</h4>Nephroblastoma and neuroblastoma survivors are at increased risk for developing components of metabolic syndrome, especially after abdominal irradiation. We emphasize that survivors treated with abdominal irradiation need alternative adiposity measurements for assessment of metabolic syndrome.Marjolein van WaasSebastian J C M M NeggersHein RaatCaroline M van RijRob PietersMarry M van den Heuvel-EibrinkPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 7, Iss 12, p e52237 (2012)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Marjolein van Waas Sebastian J C M M Neggers Hein Raat Caroline M van Rij Rob Pieters Marry M van den Heuvel-Eibrink Abdominal radiotherapy: a major determinant of metabolic syndrome in nephroblastoma and neuroblastoma survivors.
description	<h4>Background</h4>Reports on metabolic syndrome in nephroblastoma and neuroblastoma survivors are scarce. Aim was to evaluate the occurrence of and the contribution of treatment regimens to the metabolic syndrome.<h4>Patients and methods</h4>In this prospective study 164 subjects participated (67 adult long-term nephroblastoma survivors (28 females), 36 adult long-term neuroblastoma survivors (21 females) and 61 control subjects (28 females)). Controls were recruited cross-sectionally. Waist and hip circumference as well as blood pressure were measured. Body composition and abdominal fat were assessed by dual energy X-ray absorptiometry (DXA-scan). Laboratory measurements included fasting triglyceride, high density lipoprotein-cholesterol (HDL-C), glucose, insulin, low-density lipoprotein-cholesterol (LDL-C) and free fatty acids (FFA) levels.<h4>Results</h4>Median age at follow-up was 30 (range 19-51) years in survivors and 32 (range 18-62) years in controls. Median follow-up time in survivors was 26 (6-49) years. Nephroblastoma (OR = 5.2, P<0.0001) and neuroblastoma (OR 6.5, P<0.001) survivors had more components of the metabolic syndrome than controls. Survivors treated with abdominal irradiation had higher blood pressure, triglycerides, LDL-C, FFA and lower waist circumference. The latter can not be regarded as a reliable factor in these survivors as radiation affects the waist circumference. When total fat percentage was used as a surrogate marker of adiposity the metabolic syndrome was three times more frequent in abdominally irradiated survivors (27.5%) than in non-irradiated survivors (9.1%, P = 0.018).<h4>Conclusions</h4>Nephroblastoma and neuroblastoma survivors are at increased risk for developing components of metabolic syndrome, especially after abdominal irradiation. We emphasize that survivors treated with abdominal irradiation need alternative adiposity measurements for assessment of metabolic syndrome.
format	article
author	Marjolein van Waas Sebastian J C M M Neggers Hein Raat Caroline M van Rij Rob Pieters Marry M van den Heuvel-Eibrink
author_facet	Marjolein van Waas Sebastian J C M M Neggers Hein Raat Caroline M van Rij Rob Pieters Marry M van den Heuvel-Eibrink
author_sort	Marjolein van Waas
title	Abdominal radiotherapy: a major determinant of metabolic syndrome in nephroblastoma and neuroblastoma survivors.
title_short	Abdominal radiotherapy: a major determinant of metabolic syndrome in nephroblastoma and neuroblastoma survivors.
title_full	Abdominal radiotherapy: a major determinant of metabolic syndrome in nephroblastoma and neuroblastoma survivors.
title_fullStr	Abdominal radiotherapy: a major determinant of metabolic syndrome in nephroblastoma and neuroblastoma survivors.
title_full_unstemmed	Abdominal radiotherapy: a major determinant of metabolic syndrome in nephroblastoma and neuroblastoma survivors.
title_sort	abdominal radiotherapy: a major determinant of metabolic syndrome in nephroblastoma and neuroblastoma survivors.
publisher	Public Library of Science (PLoS)
publishDate	2012
url	https://doaj.org/article/8ffadfb96ee947ea9b104ad69a00df51
work_keys_str_mv	AT marjoleinvanwaas abdominalradiotherapyamajordeterminantofmetabolicsyndromeinnephroblastomaandneuroblastomasurvivors AT sebastianjcmmneggers abdominalradiotherapyamajordeterminantofmetabolicsyndromeinnephroblastomaandneuroblastomasurvivors AT heinraat abdominalradiotherapyamajordeterminantofmetabolicsyndromeinnephroblastomaandneuroblastomasurvivors AT carolinemvanrij abdominalradiotherapyamajordeterminantofmetabolicsyndromeinnephroblastomaandneuroblastomasurvivors AT robpieters abdominalradiotherapyamajordeterminantofmetabolicsyndromeinnephroblastomaandneuroblastomasurvivors AT marrymvandenheuveleibrink abdominalradiotherapyamajordeterminantofmetabolicsyndromeinnephroblastomaandneuroblastomasurvivors
_version_	1718422243115008000

Abdominal radiotherapy: a major determinant of metabolic syndrome in nephroblastoma and neuroblastoma survivors.

Ejemplares similares